Phio Pharmaceuticals Corp.
PHIO
$1.99
-$0.10-4.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -25.94% | -12.02% | -50.30% | -55.29% | -41.79% |
| Gross Profit | 25.94% | 12.02% | 50.30% | 55.29% | 41.79% |
| SG&A Expenses | 0.34% | -7.33% | -14.25% | -18.98% | -20.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.15% | -24.23% | -30.95% | -35.77% | -30.35% |
| Operating Income | 14.15% | 24.23% | 30.95% | 35.77% | 30.35% |
| Income Before Tax | 18.33% | 27.86% | 33.96% | 36.38% | 30.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.33% | 27.86% | 33.96% | 36.38% | 30.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.33% | 27.86% | 33.96% | 36.38% | 30.37% |
| EBIT | 14.15% | 24.23% | 30.95% | 35.77% | 30.35% |
| EBITDA | 13.89% | 23.92% | 30.61% | 35.54% | 30.22% |
| EPS Basic | 80.85% | 76.41% | 87.74% | 84.63% | 78.13% |
| Normalized Basic EPS | 80.48% | 76.11% | 87.66% | 85.14% | 78.54% |
| EPS Diluted | 80.85% | 76.41% | 87.74% | 84.64% | 78.14% |
| Normalized Diluted EPS | 80.48% | 76.11% | 87.66% | 85.14% | 78.54% |
| Average Basic Shares Outstanding | 97.15% | 29.14% | 680.69% | 795.03% | 895.60% |
| Average Diluted Shares Outstanding | 97.15% | 29.14% | 680.69% | 795.03% | 895.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |